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http://www.parasitesandvectors.com/content/6/1/272RESEARCH Open AccessHost serum miR-223 is a potential new biomarker
for Schistosoma japonicum infection and the
response to chemotherapy
Xing He1†, Xue Sai1†, Chao Chen1, Yuanbin Zhang2, Xindong Xu2, Dongmei Zhang1* and Weiqing Pan1,2*Abstract
Background: Numerous studies have shown that aberrant microRNA (miRNA) expression is associated with the
pathogenesis and progression of various human diseases. Hence, serum miRNAs are considered to be potential biomarkers
for the diagnosis of human diseases. This study examined whether several miRNAs known to be commonly deregulated in
liver diseases are deregulated in the serum of hosts with hepatic schistosomiasis, and thus whether they could serve as
potential markers for detection of schistosome infection and evaluation of the effectiveness of chemotherapy.
Methods: We analyzed the serum levels of six selected candidate miRNA molecules (miR-146b, miR-122, miR-223,
miR-199a-5p, miR-199a-3p, miR-34a) from mice, rabbits, buffalos and humans infected with Schistosoma japonicum
using qPCR. We evaluated liver pathology by determining the hydroxyproline content in liver tissues. Primary resident
liver cells were isolated to quantify the expression level of deregulated miRNAs. Bioinformatics analyses were also
conducted to assess the potential function of miR-223.
Results: Using a mouse model of Schistosoma japonicum infection, we found that the expression level of serum
miR-223 was significantly elevated after infection, but returned to near normal levels after the treatment with
praziquantel (PZQ). Importantly, the level of serum miR-223 reflected the extent of liver pathology post-infection.
We validated the elevated level of the circulating miR-223 in serum samples of other host species including rabbits,
buffalos and humans. In addition, our results showed that miR-223 was primarily located in the Kupffer cells, but its
expression levels were significantly up-regulated in hepatocytes, hepatic stellate cells and Kupffer cells after infection.
Bioinformatics analyses revealed a potential functional role of miR-223 in transcription regulator activity, transcription
factor activity and DNA binding.
Conclusions: This study suggested that the circulating miR-223 could serve as a potential new biomarker for the
detection of schistosome infection and the assessment of the response to chemotherapy.
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Schistosomiasis is a serious tropical parasitic disease caused
by infection with helminths in the genus, Schistosoma,
which affects more than 200 million people worldwide
[1,2]. Of the three schistosome species that infect humans,
only Schistosoma japonicum (S. japonicum) is endemic in
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reproduction in any medium, provided the or[3,4]. The primary cause of mortality from schistosomiasis
japonica is liver fibrosis, which results in portal hyperten-
sion and variceal bleeding [1]. For more than 30 years,
treatment of schistosomiasis japonica has involved adminis-
tering the anti-schistosome drug praziquantel (PZQ) [5,6].
The high prevalence of the disease is partially due to the
lack of effective detection tools for diagnosis and response
to chemotherapy. At present, however, there are no reliable
biomarkers to enable the diagnosis of schistosomiasis
infections, or to facilitate detection of the response to the
chemotherapy by PZQ.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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small, non-coding RNA molecules that regulate gene
expression post-transcription [7-9]. Numerous studies
have shown that aberrant miRNA expression is associated
with various types of human diseases including liver
diseases [10]. For example, miR-146b and miR-34a were
up-regulated in the liver tissues of patients with non-
alcoholic steatohepatitis [11], while in the CCl4 induced
liver fibrosis, miR-199a-5p and miR-199a-3p were posi-
tively and significantly correlated to the progression of
liver fibrosis [12]. Recently, miRNAs were shown to play
important roles in mediating the host-schistosome
interaction in a non-permissive host environment [13],
and in moderating regulatory T-cell function during
schistosome infection [14].
As cell-free miRNAs in serum are very stable under
harsh conditions, such as low or high pH, boiling, extended
storage, and multiple freeze-thaw cycles, they are consi-
dered important new blood-based biomarkers for disease
diagnosis and prognosis [15-17]. In addition, the expression
profiles of serum miRNAs are altered during pathological
processes, providing another valuable trait for their use as a
disease biomarker. For example, serum miR-21, miR-122
and miR-223 are elevated in patients with hepatocellular
carcinoma and chronic hepatitis and thus, have the po-
tential to serve as novel biomarkers for liver injury
[18]. Previous studies have also shown that circulating
miRNA-146a and miR-223 were significantly reduced
in septic patients [19], while serum miRNA-122 and
miRNA-192 were elevated in a mouse model of drug-
induced liver injury [20]. The alteration of miRNA ex-
pression profiles in serum of mice or patients with
schistosomiasis japonica is still largely unknown.
In this study, we hypothesized that some common
miRNAs frequently observed to be deregulated in human
liver diseases might be deregulated in the serum of hosts
with schistosomiasis japonica, and could thus serve as novel
biomarkers for the detection of schistosome infection.
To test this hypothesis, we selected six candidate serum
miRNAs for analysis (miR-146b, miR-122, miR-223,
miR-199a-5p, miR-199a-3p, miR-34a) in the murine model
of human schistosomiasis and then performed validation in
other host species including rabbits, buffalos and human
patients infected with S. japonicum.
Methods
Schistosome infection and sample preparation
Six-week-old male BABL/c mice were purchased from
the experimental animal center of the Second Military
Medicine University. Mice were exposed percutaneously to
16 S. japonicum cercaria that were shed from lab-infected
snails (Oncomelania hupensis) obtained from the National
Institute of Parasitic Disease, Chinese Center for Disease
Control and Prevention. At 42 days post-infection, a timewhen hepatic fibrosis becomes obvious, half of the mice
were treated with PZQ for three days (PZQ treated group)
and half were not treated (untreated group). Unin-
fected BALB/c mice of the same age were also used in
the experiment (uninfected group). All the mice were
sacrificed at 72 days post-infection to harvest blood
serum and liver samples.
We also conducted a separate experiment to determine
the expression level of serum miR-223 in the progression of
mouse schistosomiasis. To this end, mice were infected with
16 S. japonicum cercariae, and sacrificed at 0, 42, 56, 70 days
post-infection to harvest the serum and liver samples.
S. japonicum can infect many other animals including
buffalo that are the primary infection source of transmis-
sion in China [3]. Therefore, we analyzed the expression
level of miR-223 in serum of other hosts of schistosomes,
including rabbits, buffalos and humans. Rabbits were
infected percutaneously with 200 S. japonicum cercariae or
not infected as control. All the rabbits were sacrificed at 56
days after infection to quantify the miR-223 expression level
in the sera. Serum samples of schstosomiasis patients diag-
nosed by parasitological detection were obtained from the
field, and uninfected serum samples were obtained from
non-endemic areas as a control. All procedures performed
on animals in this study were conducted in accordance
with, and under approval of, the Second Military Medicine
University regulations.
Egg and parasite counting
The number of schistosome eggs in the liver was counted
after the liver tissue was digested by 4% KOH. Liver egg
burdens were expressed as 104 eggs per gram of liver tissue.
Perfusions of the hepatic portal system were performed
to detect the number of adult worms as described [21].
RNA extraction and reverse transcription
Blood samples were collected from hosts and centrifuged
at 3,000 × g for 10 min at room temperature to completely
remove cellular components, and the supernatant (serum)
was retained. RNA was then extracted from 100 μL of
serum using the miRNeasy mini kit (Qiagen) according
to the manufacturer’s protocol. The C. elegans spiked-in
control miRNA, cel-miR-39, was used to normalize the
technical variability of the serum RNA extraction [22].
Reverse transcription (RT) reactions were performed using
the First-Strand cDNA Synthesis Kit (TaKaRa, Dalian,
China) and miRNA-specific stem-loop primers in a 10 μL
RT reaction: 2 μL H2O, 2 μL buffer, 1 μL primer, 0.5 μL
dNTPs (10 mM), 0.25 μL RRI, 0.25 μL M-MLV and 4 μL
RNA. RT reactions were conducted in a Veriti 96-well
thermal cycler (ABI) under the following conditions: 16°C
for 30 min, 42°C for 30 min, 85°C for 5 min (then hold at
4°C). RT products were stored undiluted at 20°C prior to
running the real-time PCR reactions.
He et al. Parasites & Vectors 2013, 6:272 Page 3 of 8
http://www.parasitesandvectors.com/content/6/1/272Quantification of serum miRNAs
Quantification of serum miRNAs was performed according
to the qPCR protocols as described previously [23]. The
expression levels of miR-34a, miR-223, miR-122, miR-146b,
miR-199a-5p, miR-199a-3p were determined using the
SYBR Green Master Mix kit (TaKaRa, Dalian, China).
Cel-miR-39 was used as an internal control, and the fold
change was calculated by the 2-ΔΔCt method [24]. The
sequences of the primers used are shown in Table 1.
Hydroxyproline content assay
Hepatic fibrosis is the most important pathological
change of schistosomiasis, and the elevated hydroxy-
proline content in the liver is an informative bio-
marker for hepatic fibrosis. Therefore, we assessed
hepatic hydroxyproline content to examine liver path-
ology. Hydroxyproline content was detected using a
colorimetric assay according to the manufacturer’s in-
structions (Nanjing Jiancheng Bioengineering Insti-
tute, Nanjing, China).
Isolation of mouse hepatic stellate cells (HSCs),
hepatocytes and Kuppfer cells
Liver samples were initially digested in situ with 0.04%
collagenase type IV. They were then further digested
with 0.08% collagenase type IV while shaken for 30 mi-
nutes in a 37°C bath. The resulting cell suspension was
centrifuged at 50 × g for 4 minutes to isolate hepatocytes.
HSCs were isolated according to the method as de-
scribed previously [25]. The purity of HSCs was higher
than 95% as determined by retinoid autofluorescence.Table 1 Primers used in qPCR
Gene Primer sequence (5'-3')















Reverse CGCTTCACGAATTTGCGTGTCATKuppfer cells were isolated using positive selection
with magnetic CD11b antibody beads and magnetic
columns (MACS, Miltenyi, Auburn, CA) [26]. FACS-
Calibur analysis demonstrated >90% purity after la-
beling purified cells with CD11b-FITC antibody
(Miltenyi; Auburn, CA).
Gene ontology (GO) analysis
GO analysis was used to analyze the potential function
of miRNAs [27]. A two-tailed Fisher’s exact test and
a χ2 test were used to classify the GO category. The
false discovery rate (FDR) was calculated to correct the
P-value. We chose only GOs that had a P-value of
<0.001 and a FDR of <0.05.
Statistical analyses
All results are reported as means ± standard deviations
and compared between groups using two-tailed Student’s
t-test or one-way ANOVA. Data were considered statis-
tically significant at P < 0.05.
Results
Changes of hydroxyproline content in liver tissues
Hepatic fibrosis is the most important pathological
change of schistosomiasis while the elevated hydroxy-
proline content in the liver is an informative biomarker
for hepatic fibrosis. Therefore, we assessed hepatic hy-
droxyproline content to examine liver pathology. As
shown in Figure 1A, hydroxyproline content in the
liver tissue of mice in the untreated group increased
significantly after infection. After treatment with PZQ,
however, the liver pathology was significantly allevi-
ated and returned to near normal level (see results for
the treated group; Figure 1A). In addition, we mea-
sured the hydroxyproline content at various time
points post infection and showed that the hydroxypro-
line content in the liver of infected mice was increased
with the time extended (Figure 2A).
Expression levels of miRNAs in sera of mice
with schistosomiasis
To identify miRNAs that reflected the schistosome
infections and PZQ chemotherapy, six miRNA candidates
(miR-146b, miR-122, miR-223, miR-199a-5p, miR-199a-3p,
miR-34a) were selected for analysis in serum that were
commonly deregulated in human liver diseases. In mouse
hosts, quantitative PCR result revealed that circulating
miR-223, miR-122 and miR-34a were significantly elevated
after infection (Figure 1B-D). Conversely, levels of serum
miR-199a-3p, miR-199a-5p, and miR-146b in mice
decreased after infection (Figure 1E-G). Only one serum
miRNA in infected mice, however, decreased significantly
after the PZQ treatment (miR-223, Figure 1B).
Figure 1 Alteration of miRNA expression profiles in serum of infected mice with schistosomiasis japonica. Mice were infected percutaneously
with 16 S. japonicum cercariae or remained uninfected (normal group, blank square). Half of the infected mice were treated with PZQ for 3 days
(PZQ treated group, black triangle) and half were not treated (untreated group, black square). All the mice were sacrificed at 72 days after infection to
harvest the serum and liver samples. (A) Hydroxyproline content of liver samples of mice from the three groups was detected. Expression levels of
serum miR-223 (B), miR-122 (C), miR-34a (D), miR-199a-5p (E) miR-199a-3p (F), and miR-146b (G) were detected in the three groups of mice. The data
shown are measurements from individual mice. The bars designated the means for each group.
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of schistosomiasis
Next, we analyzed the expression level of serum miR-
223 in the progression of mouse schistosomiasis. To
this end, mice were infected with 16 S. japonicum cer-
cariae, and sacrificed at 0, 42, 56 and 70 days after
infection. As expected, the level of circulating miR-
223 increased significantly during the course of
infection (Figure 2B). Importantly, the level of serum
miR-223 was significantly correlated with the hydro-
xyproline content in the liver tissue (r = 0.808, P <
0.001), which suggests that the level of serum miR-
223 could reflect the extent of liver pathology after
infection (Figure 2C). To investigate any correlation
of the serum miR-223 level with the infection intensity, we
counted the liver eggs and the adult worms at various time
points post infection. As shown in Figure 2D and 2E, the
liver egg burden was gradually increased with the time ex-
tended, but the adult parasites living in the mesentericveins remained constantly at the three time points.
Moreover, the serum miR-223 level was significantly
correlated with the liver egg burden (r = 0.603, P =
0.008, Figure 2F).
Expression level of circulating miR-223 in human and
other animal models with schistosomiasis
Schistosomiasis japonica is a zoonotic parasitic disease.
In addition to mice, S. japonicum can infect other ani-
mals such as rabbit, buffalo etc. The latter is the pri-
mary infection source of S. japonicum transmission in
China [3]. Therefore, we analyzed the expression level
of miR-223 in serum of other host species of schis-
tosome, including rabbits, buffalos and humans. As
shown in Figure 3, the miR-223 expression level was
obviously elevated in the serum of infected rabbit,
buffalo and human, which validated the results of the
miR-223 obtained from the mouse model of human
schistosomiasis.
Figure 2 Correlation between serum miR-223 expression level and liver hydroxyproline content in the infected mice. Mice were infected
percutaneously with 16 S. japonicum cercariae, and sacrificed at 0, 42, 56, 70 days after infection to harvest the serum and liver samples (n = 6).
Hydroxyproline content of liver samples (A) and miR-223 expression level of serum samples (B) from the four groups were determined,
respectively. (C) Correlation analysis between the liver hydroxyproline content the serum miR-223 expression level was performed. Eggs trapped
in the liver tissue (D) and adult parasites living in the mesenteric veins (E) were counted. (F) Correlation analysis between the liver egg burden
and the serum miR-223 expression level was performed.
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We isolated the primary resident livers cells, including
hepatocytes, hepatic stellate cells (HSCs) and Kupffer
cells, to quantify the expression level of miR-223. We found
that miR-223 was primarily located in the Kuppfer cells of
both infected and uninfected livers (Figure 4A). However, a
significant elevated expression level of miR-223 was detected
in not only the Kuppfer cells, but also hepatocytes and
HSCs after infection (Figure 4B). Bioinformatics analysesFigure 3 Expression level of the serum miR-223 in rabbit, buffalo and hu
200 S. japonicum cercariae or not infected as control. All the rabbits were sacrific
the sera. (B, C) The expression level of serum miR-223 was detected in serum sa
detection and uninfected individuals as control. The data shown are measurem(TargetScan analysis [28] and Gene ontology analysis [29])
revealed a potential role of miR-223 in transcription
regulator activity, transcription factor activity and DNA
binding (Figure 4C).
Discussion
Circulating miRNAs are stable even if subjected to harsh
conditions, and their expression profiles are often altered
in numerous human diseases including liver diseases [17].
These make them ideal candidates for use as biomarkersman with schistosomiasis. (A) Rabbits were infected percutaneously with
ed at 56 days after infection to quantify the miR-223 expression level in
mples of schistosomiasis patients or buffalos diagnosed by parasitological
ents from individuals. The bars designate the means for each group.
Figure 4 Expression level of miR-223 in resident liver cells. Mice were infected percutaneously with 16 S. japonicum cercariae or not infected
as control, and sacrificed at 56 days after infection to isolate the hepatocytes, HSCs and Kupffer cells. Relative miR-223 expression in comparison
with uninfected hepatocytes was determined by qPCR (A), and the miR-223 expression levels of hepatocytes, HSCs and Kupffer cells after
infection were analyzed (B). The potential role of miR-223 was analyzed by bioinformatics analyses (C).
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of the characteristically changed serum miRNAs in the
pathogenesis and progression of human diseases has
been used to identify new blood-based biomarkers for
disease diagnosis and prognosis. Schistosomiasis is a
worldwide parasitic disease that causes liver fibrosis
and ultimately the death of the host. Currently, there
are still no reliable biomarkers for the early diagnosis
of schistosomiasis or the detection of disease progress
after administration of therapeutic drugs, such as PZQ.
In this study, we evaluated the levels of six candidate
serum miRNAs (known to be commonly deregulated in
human liver diseases) in multiple host species infected
with S. japonicum. Using a mouse model of schistoso-
miasis japonica, we found that the expression level of
serum miR-223 was significantly elevated after infection,
yet returned to near normal levels after treatment with
the anti-helminth drug PZQ. Importantly, we found that
the level of serum miR-223 reflected the extent of liver
pathology post-infection. In addition, we observed that
circulating miR-223 was also significantly elevated in
other hosts infected with S. japonicum, including rabbits,
buffalos and humans, validating the results of the mur-
ine model. It is true that the elevated level of the serum
miR-223 was associated with schistosomiasis, but it may
not be specifically associated with the disease because
the elevated level of the miR-223 was also observed in
chronic hepatitis [18]. The explanation could be that al-
teration of a circulating miRNA can be indicative ofpathological changes for some diseases sharing some
common pathogenesis processes such as inflammation,
immune response, or fibrosis etc. Thus, those individual
circulating miRNAs can serve as the biomarkers for
those diseases sharing some common pathogenesis pro-
cesses. For examples, serum miR-155 is the potential
biomarker for B-cell lymphoma [30] but also for other
cancers such as breast cancer [31], ovarian cancer [32],
and pancreatic cancer [33]; Serum miR-92 is the poten-
tial biomarker for colon cancer [34], but also leukemia
[35], and ovarian cancer [32]; Circulating miR-223 is the
potential biomarker for chronic hepatitis [18], but also
for schistosomiasis observed in this study. Due to cur-
rently lack of the effective tools for detection of schisto-
some infection, the serum miR-223 identified in this study
should be useful in combination with other tools such as
immunodiagnostic assays or other molecular markers to
be identified and available for epidemiological information
for the detection of schistosome infection.
In addition to the association of the serum miR-223
with schistosomiasis, we also showed that the levels of the
circulating miR-223 were significantly declined and
returned to normality after treatment of the host with the
anti-helminth drug, praziquantel. This finding is most in-
teresting because it is specifically associated with the ex-
tent of hepatic schistosomiasis and has an important
potential prospect for application. The schistosome para-
sites live in the mesenteric veins. Currently there is no
specific molecular tool available to detect the efficacy of
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a tool is extremely important for effectively targeting treat-
ment to all the infected hosts and currently the schisto-
somiasis elimination program is based on the control of
infection sources. We showed both hydroxyproline con-
tent and the circulating miR-223 were returned to near
normality within one month after PZQ treatment, indi-
cating the serum miR-223 marker is sensitive to chemo-
therapy and could be potentially developed as new tool
for measurement of the response to chemotherapy.
It is widely accepted that circulating miRNAs are derived
either via passive release from injured tissues [36] or via
active release from cells through microvesicles [37]. In this
study, we isolated the primary hepatocytes, HSCs and
Kupffer cells from the infected and uninfected livers to
quantify the expression level of miR-223. We found
miR-223 was primarily located in the Kupffer cells, and
the expression level of miR-223 was significantly up-
regulated in all these three types of resident liver cells
post-infection, which suggests that the elevated serum
miR-223 is derived from the infected liver. Nowadays, it is
well acknowledged that the regulation and function of
miRNAs is cell-type specific. Considering the Kupffer cells
are essential for the development of schistosomiasis-
induced inflammation and fibrosis [38], our data implied
that miR-223 could play an important role in the patho-
genesis and progression of schistosomiasis japonica via
regulating the function of Kupffer cells. Importantly, bio-
informatics analyses showed that miR-223 potentially
functions in transcription regulator activity, transcription
factor activity and DNA binding. This suggested that
miR-223 could regulate the transcription of some im-
portant genes in the Kupffer cells to modulate their
function. Taken together, our data proved that miR-233
is a schistosomiasis-associated miRNA.
Conclusions
These results indicate that miR-233 was a schistosomiasis-
associated miRNA, and thus circulating miR-223 may
serve as a new potential biomarker for the detection of
schistosome infection and the assessment of the response
to chemotherapy.
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